Insider Selling: Guardian Pharmacy Services, Inc. (NYSE:GRDN) Director Sells 1,084,276 Shares of Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) Director John Ackerman sold 1,084,276 shares of Guardian Pharmacy Services stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total transaction of $21,859,004.16. Following the transaction, the director now directly owns 200,099 shares in the company, valued at $4,033,995.84. This trade represents a 84.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

John Ackerman also recently made the following trade(s):

• On Wednesday, May 28th, John Ackerman sold 201,303 shares of Guardian Pharmacy Services stock. The shares were sold at an average price of $20.16, for a total transaction of $4,058,268.48.

Guardian Pharmacy Services Price Performance

Guardian Pharmacy Services stock traded up $0.12 during trading hours on Monday, reaching $21.29. The stock had a trading volume of 249,308 shares, compared to its average volume of 168,739. The company has a fifty day simple moving average of $23.18 and a 200-day simple moving average of $22.01. Guardian Pharmacy Services, Inc. has a 52 week low of $14.16 and a 52 week high of $26.91.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01). The firm had revenue of $329.31 million for the quarter, compared to the consensus estimate of $321.21 million. As a group, equities analysts expect that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on GRDN. Wall Street Zen downgraded Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a report on Saturday, May 24th. Raymond James set a $28.00 price target on Guardian Pharmacy Services and gave the stock an "outperform" rating in a research report on Wednesday, May 14th. Finally, Truist Financial reiterated a "buy" rating and issued a $28.00 price objective (up previously from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nuveen Asset Management LLC grew its position in shares of Guardian Pharmacy Services by 2.9% in the 4th quarter. Nuveen Asset Management LLC now owns 547,140 shares of the company's stock worth $11,085,000 after buying an additional 15,550 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in shares of Guardian Pharmacy Services during the fourth quarter valued at approximately $544,000. Rhumbline Advisers bought a new position in shares of Guardian Pharmacy Services during the fourth quarter valued at approximately $149,000. Northern Trust Corp purchased a new stake in Guardian Pharmacy Services in the fourth quarter worth $1,479,000. Finally, New York State Common Retirement Fund boosted its holdings in Guardian Pharmacy Services by 17.9% in the fourth quarter. New York State Common Retirement Fund now owns 278,548 shares of the company's stock valued at $5,643,000 after acquiring an additional 42,368 shares in the last quarter.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.